Search

Displaying results 5481 - 5490 of 10000 in total
  1. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    MaxAdFVIII is an adenoviral vector that expresses the full-length human Factor VIII (hFVIII) cDNA. First developed by GenStar, it is being investigated for the treatment of hemophilia.

  2. Drug

    Bicuculline

    go.drugbank.com/drugs/DB11562
    Experimental

    It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.

  3. Drug

    BIIB015

    go.drugbank.com/drugs/DB06304
    Investigational

    It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.

  4. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

  5. Drug

    Exisulind

    go.drugbank.com/drugs/DB06246
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    NOP-1A

    go.drugbank.com/drugs/DB15208
    Investigational

    NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).

  7. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

  8. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  9. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  10. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.